Sun Pharma Reports Strong Q1 FY27 Results, Reporting 10.1% Sales Growth and High Margins

Sun Pharma Reports Strong Q1 FY27 Results, Reporting 10.1% Sales Growth and High Margins​

Sun Pharmaceutical Industries Limited announced its consolidated financial results for the first quarter of fiscal year 2026-27, highlighting significant growth in sales and strong profitability across key business segments.

The company reported total revenue from operations at Rs 151,835.5 million for the quarter ended June 30, 2026. This represents a 10.1% year-on-year increase. The consolidated entity maintained a healthy EBITDA margin of 28.9%, with an EBITDA figure reaching Rs 44,103.8 million. Furthermore, the adjusted net profit stood at Rs 30,894 million, reflecting steady performance in profitability.

The results underscore Sun Pharma's global reach and momentum across various therapeutic areas.

Consolidated Financial Snapshot for Q1 FY27​

Segment Performance and Operational Highlights​

Performance was led by the Indian market and innovative medicines globally. Formulations sales in India registered a growth of 16%, reaching Rs 54,748.9 million. These formulations account for 36.1% of total consolidated sales, representing a gain of 0.3 percentage points to reach an 8.5% market share according to the Pharmarack MAT June-2026 report.

In global innovative medicines, sales stood at US$ 351 million, marking a 12.8% increase and contributing 21.9% of total consolidated sales for the quarter.

The North American segment reported declines, with formulations sales in the US reaching US$ 40,419.1 million, which is down 9.7%. US Formulations constitute approximately 26.6% of the total consolidated sales. Meanwhile, Emerging Markets (EM) formulations achieved a revenue of US$ 29,456.3 million, or 4.2% higher than the previous year, making up 19.4% of total consolidated sales. The Rest of World (ROW) formulations recorded sales at US$ 20,685.8 million and accounted for 13.6% of total consolidated sales.

Strategy and Research & Development Focus​

Sun Pharma continues to invest heavily in its pipeline and strategic acquisitions. In the quarter, R&D expenditure amounted to Rs 8,263.5 million, which is equivalent to 5.4% of sales.

The company maintained a robust portfolio in the US market, boasting 57 approved NDAs while 13 are pending US FDA approval. The innovative medicines pipeline includes several key candidates: Ilumya for psoriatic arthritis (supplement filed with US FDA), Fibromun for soft tissue sarcoma glioblastoma (Phase 2 completed), GL0034 for type 2 diabetes (Phase 2), and Nidlegy TM for locally advanced melanoma BCC.

In a major strategic move, the Group signed a definitive agreement on April 27, 2026, to acquire all outstanding shares of Organon & Co. The transaction is structured as an all cash deal with an enterprise valuation of USO 11.75 billion and each share being purchased for USO 14.00.

Sun Pharma's API portfolio generated external sales of Rs 5,972 million, registering a 10.5% increase.

SUNPHARMA Stock Price Movement​

Today, Sun Pharmaceutical Industries Limited saw its stock rally in the post-market session, closing higher by 0.69% at ₹2014.90 after settling a gain of ₹13.80. The company's shares achieved significant momentum as over two million units were traded, firmly establishing it near its 52-week high level.